2015 Towards an HIV Cure Symposium
18 & 19 July 2015

DAY 1

Opening Session


Keynote Address: Progress and Challenges in HIV Cure Research
Daniel Kuritzkes
Brigham & Women’s Hospital, Harvard Medical School, United States


Community Speaker: Community Involvement in HIV Cure-related Research: Not Just Guinea Pigs
Matthew Sharp
Long-Term Survivor, HIV Education and Advocacy Consultant, United States



Oral Abstract Session 1: Pathways to Establishing and Maintaining HIV Latency


Invited Speaker: HIV-1 broadly neutralizing antibodies: Potential role in HIV treatment approaches

John Mascola
Vaccine Research Center, NIAID/NIH, United States


OA1-1: CTLA-4-expressing memory CD4+ T-cells are critical contributors to SIV viral persistence
Colleen McGary
Emory University, United States


OA1-2: Molecular Determinants of HIV-1 Permissiveness and Persistence in Gut-Homing CD4+ T-Cells Expressing the Th17 Marker CCR6
Delphine Planas
CHUM-Research Center, University of Montreal, Canada


OA1-3: Dasatinib preserves SAMHD1 antiviral activity in CD4+ T cells treated with IL-7
Jose Alcami
Instituto de Salud Carlos III, Spain


OA1-4 LB: Estrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs
Jonathan Karn
Case Western Reserve University School of Medicine, United States


Roundtable: Advancing Paediatric HIV Cure Research



Chair: Jintanat Ananworanich
US Military HIV Research Program, United States

Panelists:
Marie Elizabeth Theunissen
FAMCRU, South Africa


Hugo Soudeyns
CHU Sainte-Justine Research Center and Université de Montréal, Canada


Deborah Persaud
John Hopkins University, United States


Ann Chahroudi
Emory University School of Medicine, United States


Daria Hazuda
Merck, United States



Oral Abstract Session 2: Activating Latent HIV Infection in vitro and in vivo


Invited Speaker: Immune recognition following latency reversal
Marcus Altfeld
Heinrich-Pette Institute, Leibniz Institute for Experimental Virology, Germany


OA2-1: Histone deacetylase inhibitors alter the accumulation of spliced HIV mRNA - implications for virus production
Talia Mota
University of Melbourne, Peter Doherty Institute, Australia


OA2-2: Latency reversal Agent (LRA) Romidepsin Reactivates Latent Virus in Two Rhesus Macaque (RM) Models of Controlled SIV Infection in the Absence of Antiretroviral Therapy (ART)
Benjamin Policicchio
University of Pittsburgh, United States


OA2-3: Vorinostat, Panobinostat, and Romidepsin Nonselectively Activate Transcription from Quiescent HIV-1 Proviruses in HIV-infected Individuals on Long-term Suppressive Anti-retroviral Therapy
Kirston Barton
University of Sydney, Westmead Millennium Institute, Australia


OA2-4: Modulation of HERV family expression after treatment with HDAC inhibitors
Miguel de Mulder Rougvie
George Washington University, United States


OA2-5: Ingenol Efficiently Reactivates Latent HIV in cells from aviremic patients
Vicente Planelles
University of Utah, United States


OA2-6 LB: CD4 Mimetics Sensitize HIV-1-Infected Cells to ADCC
Andres Finzi
The CHUM Research Center, University of Montreal & McGill University, Canada



Roundtable: Combination Therapy Trials


Chair: Daniel Kuritzkes
Brigham & Women’s Hospital, Harvard Medical School, United States

Panelists:
Brigitte Autran
Hôpital Pitié Salpêtrière, CIMI-Paris, UPMC/INSERM U1135, France


Joseph Eron
University of North Carolina, United States


Irina Tcherepanova
Argos Therapeutics, Inc., United States


Jeffrey Lifson
Frederick National Laboratory for Cancer Research, United States


David Evans
Project Inform, United States

 

With the support of: